Leading today. Redefining tomorrow.
The #1 liquid biopsy for a reason.1
Covers 740+ genes
and is the first to
unlock epigenomics2,3*
Important note: Guardant360 Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
Powered by Guardant Infinity™
Highest sensitivity
with a reportable range
down to 0.001% MAF2
Broad coverage
with >92% of patients
paying $0‡
MAF, mutant allele fraction.
*Guardant360 Liquid is the first and only commercially available liquid biopsy to unlock genomics and epigenomics from a single input.
†Median turnaround time from sample receipt to results.
‡More than 92% of patients are assigned $0 by their insurance for a Guardant360 test.
Home Screening Monitoring: MRD Monitoring: Treatment Response Treatment Selection
Fast results
in 7 days2†